PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
A double-blind RCT investigated capsules containing 300 mg of standardized extract (2% flavonoids) as an adjuvant treatment [PMID:34506937]. However, another randomized cross-over study using 3 g of leaf infusions per day found no acute or chronic effects on plasma glucose or glycated hemoglobin [PMID:2201413].
A quasi-experimental study found that drinking 0.4% B. forficata tea twice daily for 3 months significantly decreased triglycerides (by 48 mg/dL) and total cholesterol (by 17 mg/dL) [PMID:30817232].
Safety & adverse effects
Pregnancy & lactation
Evidence summary
PubMed sources
- 1.PMID: 29168921 (2018) — Bauhinia forficata in the treatment of diabetes mellitus: a patent review. · Expert opinion on therapeutic patents
- 2.PMID: 34506937 (2022) — Clinical efficacy of capsules containing standardized extract of Bauhinia forficata Link (pata-de-vaca) as adjuvant treatment in type 2 diabetes patients: A randomized, double blind clinical trial. · Journal of ethnopharmacology
- 3.PMID: 37251729 (2023) — Volatile profile and micropropagation conditions of Bauhinia forficata Link. · 3 Biotech
- 4.PMID: 36432781 (2022) — Bauhinia forficata Link, Antioxidant, Genoprotective, and Hypoglycemic Activity in a Murine Model. · Plants (Basel, Switzerland)
- 5.PMID: 31999500 (2020)